Intraoperative Imaging of Breast Cancer With Indocyanine Green (ICG)

• ClinicalTrials.gov Identifier: NCT01796041
• Recruitment Status: Completed
• First Posted: February 21, 2013
• Last Update Posted: January 28, 2021
• Sponsor: Abramson Cancer Center of the University of Pennsylvania
• Information provided by (Responsible Party): Abramson Cancer Center of the University of Pennsylvania

Study Description

Brief Summary:

According to the World Health Organization, breast cancer is the most common cancer in women, and is responsible for 686,000 new cases every year. The WHO also posit that nearly 420,000 women perished from the disease in 2002. Surgery remains the best option for patients presenting with operable Stage I, II or III cancers. Breast conservation surgery has been shown to be as efficacious as mastectomy. About 60-70% of these women with operable breast cancer are breast conservation candidates. However, the need to achieve negative tumor margins often requires a second operation (re-excision) in up to 70% of the women having lumpectomy surgery. Currently, tumor margins assessment in the operating room is often assessed grossly by palpation. The ability to evaluate tumor margin using our proposed intraoperative imaging technique may provide the surgeon with an alternative, and hopefully, more sensitive method to assess tumor margins which may decrease re-excision and the morbidity associated with additional surgery, and, perhaps, lower the risk of local regional recurrence.

Condition or disease	Intervention/treatment	Phase
Invasive Ductal Carcinoma; Invasive Lobular Carcinoma; Ductal Carcinoma	Drug: Indocyanine Green	Early Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery
• Study Start Date: July 2011
• Actual Primary Completion Date: November 9, 2016
• Actual Study Completion Date: November 9, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: IV Injection of ICG	Drug: Indocyanine Green; Other Names: ICG; The chemical formula is C45H47N2O6S2Na

Outcome Measures

Primary Outcome Measures :

1. Identification [ Time Frame: After infusion of ICG ]
   The primary outcome will be the proportion of patient's tumors identified by ICG uptake versus the proportion of patients identified by visual and tactile methods by the surgeon (considered standard of care)

Secondary Outcome Measures :

1. Evaluation [ Time Frame: 0-5 years after surgery ]
   a) Correlate detected ICG excitation in shave lumpectomy margins with quantity of residual disease in histologic sections.
2. Evaluation [ Time Frame: 0-5 years after surgery ]
   b) evaluate the rate of re-excision in participants compared to a matched case- control cohort with similar clinicopathological characteristics undergoing breast conservation surgery.
3. Evaluation [ Time Frame: 0-5 years after surgery ]
   C) evaluate progression free survival in our study cohorts

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Adult patients over 18 years of age
2. Women with newly diagnosed, operable invasive ductal carcinoma, invasive lobular carcinoma or ductal carcinoma who are deemed breast conservation surgery candidates (i.e. lumpectomy +/- sentinel node biopsy).
3. Breast cancer needs to be unifocal as determined by clinical parameters, e.g. by palpation or by breast imaging findings including mammogram, US and/or breast MRI. Multifocal disease, i.e. cancer confined to one quadrant, is eligible if patients are deemed breast conservation candidates.
4. Subject capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

1. Newly diagnosed breast cancer patients who are not breast conservation candidates and those with multicentric breast cancer (breast cancer documented in multiple quadrants by breast imaging or exam)
2. Pregnant women as determined by urinary or serum beta human chorionic gonadotropin (hCG) within 72 hours of surgery
3. Subjects with a history of iodide allergies

4. At-risk patient populations

   1. Homeless patients
   2. Patients with drug or alcohol dependence
   3. Patients unable to participate in the consent process

Contacts and Locations

Locations

United States, Pennsylvania

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

Abramson Cancer Center of the University of Pennsylvania

More Information

• Responsible Party: Abramson Cancer Center of the University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT01796041
• Other Study ID Numbers: UPCC 12111; 813695 ( Other Identifier: UPenn IRB Protocol # )
• First Posted: February 21, 2013
• Last Update Posted: January 28, 2021
• Last Verified: February 2018

Additional relevant MeSH terms:

Carcinoma; Carcinoma, Ductal; Carcinoma, Lobular; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Neoplasms, Ductal, Lobular, and Medullary; Breast Neoplasms; Neoplasms by Site; Breast Diseases; Skin Diseases